Lord, Abbett & Co
HCAT icon

Lord, Abbett & Co’s Health Catalyst HCAT Stock Holding History

Lord, Abbett & Co’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-250,998
Closed -$6.56M – 591
2022
Q1 		$6.56M Buy
250,998
+4,547
+2% +$129K 0.02% 526
2021
Q4 		$9.76M Sell
246,451
-2,409
-1% -$110K 0.02% 492
2021
Q3 		$12.4M Buy
248,860
+41,618
+20% +$2.27M 0.03% 492
2021
Q2 		$11.5M Sell
207,242
-19,770
-9% -$1.05M 0.03% 507
2021
Q1 		$10.6M Buy
227,012
+58,792
+35% +$2.85M 0.03% 511
2020
Q4 		$7.32M Sell
168,220
-4,652
-3% -$172K 0.02% 572
2020
Q3 		$6.33M Sell
172,872
-9,688
-5% -$329K 0.02% 541
2020
Q2 		$5.33M Buy
182,560
+35,398
+24% +$978K 0.02% 566
2020
Q1 		$3.85M Sell
147,162
-26,402
-15% -$807K 0.02% 564
2019
Q4 		$6.02M Buy
173,564
+895
+0.5% +$29.6K 0.02% 583
2019
Q3 		$5.46M Buy
+172,669
New +$6.8M 0.02% 623

Other funds holding HCAT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Lord, Abbett & Co's HCAT Position: Q2 2022 in Review

Lord, Abbett & Co sold out of Health Catalyst (HCAT) in Q2 2022, closing a stake of 250,998 shares — an estimated $6.56M sold.

Lord, Abbett & Co first reported a position in HCAT in Q3 2019 and held it in 11 quarters. The position peaked at $12.4M in Q3 2021. 179 funds tracked by Wall St. Rank hold HCAT as of Q2 2022.

  • Lord, Abbett & Co reported no remaining Health Catalyst position as of Q2 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 250,998 Health Catalyst shares in Q2 2022, an estimated $6.56M.
  • Lord, Abbett & Co first reported a position in Health Catalyst in Q3 2019 and held it in 11 quarters.
  • Lord, Abbett & Co's Health Catalyst position peaked at $12.4M in Q3 2021.
  • 179 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2022.

Based on Lord, Abbett & Co's 13F filing for Q2 2022, filed 12 Aug 2022.